MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
14.51
-0.13
-0.89%
Pre Market: 14.55 +0.04 +0.28% 06:29 05/21 EDT
OPEN
14.70
PREV CLOSE
14.64
HIGH
14.75
LOW
14.14
VOLUME
173
TURNOVER
0
52 WEEK HIGH
17.75
52 WEEK LOW
6.99
MARKET CAP
1.73B
P/E (TTM)
-13.9105
1D
5D
1M
3M
1Y
5Y
1D
Top Executive Sells Thousands of Arcutis Biotherapeutics Shares!
TipRanks · 18h ago
Director Makes Bold Move with Arcutis Biotherapeutics Stock Purchase
TipRanks · 1d ago
Weekly Report: what happened at ARQT last week (0512-0516)?
Weekly Report · 2d ago
Director Makes Bold Move with Major Stock Purchase in Arcutis Biotherapeutics
TipRanks · 5d ago
Arcutis announces publication of Genital Psoriasis Wellness Consortium statement
TipRanks · 6d ago
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
Barchart · 6d ago
Director’s Bold Move: A Major Investment in Arcutis Biotherapeutics
TipRanks · 05/14 02:08
Weekly Report: what happened at ARQT last week (0505-0509)?
Weekly Report · 05/12 09:14
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.